Skip to main content

Table 2 Summary of the imaging protocols for the dosimetry used in the Iluminet trial (P) and each of the alternative treatment planning strategies tested in the current analysis (A–I) (for further details, see the main text)

From: Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy

Treatment planning strategy Description Planar imaging SPECT Individualized, dosimetry-based treatment (yes/no)
Method P (as per clinical trial protocol) Hybrid dosimetry in each cycle Whole-body scintigraphy at 1, 24, 48 or 96 h and 168 h 1 SPECT at 24 h Yes
Method A 4 cycles to all patients Whole-body scintigraphy at 1, 24, 48 or 96 h and 168 h 1 SPECT at 24 h No
Method B Planar-based dosimetry 1st cycle only Whole-body scintigraphy at 1, 24, 48 or 96 h and 168 h, 1st cycle only None Yes
Method C Planar-based dosimetry in each cycle Whole-body scintigraphy at 1, 24, 48 or 96 h and 168 h None Yes
Method D Hybrid dosimetry 1st cycle only Whole-body scintigraphy at 1, 24, 48 or 96 h and 168 h, 1st cycle only 1 SPECT at 24 h, 1st cycle only Yes
Method E Hybrid dosimetry 1st cycle + 1 SPECT/cycle thereafter Whole-body scintigraphy at 1, 24, 48 or 96 h and 168 h, 1st cycle only 1 SPECT at 24 h Yes
Method F 1 SPECT/cycle, identical effective halftime (51.6 h) assumed None 1 SPECT at 24 h Yes
Method G 1 SPECT/cycle at 96 h None 1 SPECT at 96 h Yes
Method H 1 SPECT at 96 h 1st cycle only None 1 SPECT at 96 h, 1st cycle only Yes
Method I 1 planar image at 96 h in each cycle Whole-body scintigraphy at 96 h None Yes